NCT04787042View on ClinicalTrials.gov

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

316

Participants

Timeline

Start Date

August 6, 2021

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions
CancerSolid TumorMelanomaRenal Cell CarcinomaTriple-negative Breast CancerNon Small Cell Lung CancerSquamous Cell Carcinoma of the Head and NeckCarcinomaMSI-High
Interventions
BIOLOGICAL

ST-067

ST-067 is an engineered variant of human interleukin-18.

BIOLOGICAL

Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA]

Obinutuzumab is a humanized anti-CD20 monoclonal antibody of the IgG1 subclass. It recognizes a specific epitope of the CD20 molecule found on B-cells.

BIOLOGICAL

pembrolizumab

Pembrolizumab is a potent humanized immunoglobulin G4 monoclonal antibody.

Trial Locations (6)

14263

RECRUITING

Roswell Park Cancer Institute, Buffalo

33612

RECRUITING

Moffitt Cancer Center, Tampa

80218

RECRUITING

Sarah Cannon Research Institute at HealthONE, Denver

85258

RECRUITING

HonorHealth Research Institute, Scottsdale

06519

RECRUITING

Yale Cancer Center, New Haven

02114

RECRUITING

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Simcha IL-18, Inc.

INDUSTRY